Skip to main content
Some text as placeholder. In real life you can have the elements you have chosen. Like, text, images, lists, etc.
What are you looking for?

COVID-19 Resource Center

Syneos Health Supports ACRO Statement on COVID-19 Vaccines

The Association of Clinical Research Organizations (ACRO) represents clinical research and technology companies that provide a variety of specialized tools and services to support the development of new pharmaceuticals, biologics and medical devices. We are proud of the role our member companies have played in the development of COVID vaccines, which have been supported by overwhelmingly positive and reliable data. Going forward, an increasing number of governments, healthcare systems, research sites and sponsors are requiring vaccination for the protection of clinical trial participants, medical and healthcare staff, and others. In keeping with our industry’s ongoing commitment to public health and patient safety, ACRO supports our member companies as they strongly recommend that their employees be fully vaccinated as quickly as possible, based on vaccine availability at the country and local level. 

Collaborating to Address the Challenge of COVID-19

We are here to listen, collaborate and be agile as we navigate this global health crisis together. During this time, we continue to look ahead and evolve our ways of working, ensuring that our processes, people and innovative technologies enable the continued development and delivery of medicines to patients worldwide.

Explore this page to learn more about our preparedness, resources and perspectives on COVID-19.

Corporate Updates

During this challenging time we are committed to frequent, clear communication about the steps we are taking in response to the COVID-19 crisis, with the goal of ensuring that the vital work of delivering new therapies to patients continues.

Unparalleled Product Development Expertise

Clinical trials to test vaccines and treatments during a pandemic demand extreme speed in start-up, a rapid operational tempo and access to subjects in high-risk areas for the targeted disease. Getting these products to market requires an agile partner with deep therapeutic expertise, novel strategy and flawless execution.

COVID-19 Multimedia

The Syneos Health Podcast

Our Coronavirus Special Edition Podcast Series explores, from an operational standpoint, the impact of COVID-19 on the biopharmaceutical industry, the challenges for rapid R&D in an outbreak environment, and the opportunities to leverage technology and innovation to address these critical issues.

For more perspectives on helpful strategies at this time –
from virtual trials to crisis communications:

Visit Our Insights Hub

COVID-19 Special Initiative: Ventilator Initiative Task Force

A critical shortage of mechanical ventilators is anticipated in many countries, including the United States, because of the COVID-19 pandemic. Recent FDA guidance provides for the use existing hospital BiPAP (bi-level positive airway pressure) machines on an emergency basis to spare mechanical ventilation if necessary. Syneos Health has launched the Ventilator Initiative Task Force as a platform for mobilizing awareness and action, and to support healthcare professionals with education, training and research.

Interested in Syneos Health?